Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Immunovant (NASDAQ:IMVT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $28.00. They now have a "neutral" rating on the stock.
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]